Spread | 0.19 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 60 |
Open | 60.05 |
1-Year Change | 38.65% |
Day's Range | 59.34 - 60.74 |
Vaxcyte Inc. is a vaccine company, which is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes VAX-24, VAX-XP, VAX-A1 and VAX-PG. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine (PCV). The Company's second PCV candidate, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. Its VAX -PG is being developed as a protein vaccine for the treatment of periodontitis.
BRIEF: For the fiscal year ended 31 December 2021, Vaxcyte Inc revenues was not reported. Net loss increased 12% to $100.1M. Higher net loss reflects General and administrative - Balancing increase of 49% to $18.5M (expense), Stock-based Compensation in SGA increase of 90% to $6.8M (expense), Stock-based Compensation in R&D increase from $1.9M to $4M (expense).